Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

RecruitingRare disease

Study on the Safety and Effects of Sparsentan for Children with Proteinuric Kidney Diseases

Verified siteInvestigationalNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying certain kidney diseases known as proteinuric glomerular diseases. These include conditions like Focal Segmental Glomerulosclerosis (FSGS), Minimal Change Disease (MCD), Immunoglobulin A Nephropathy (IgAN), Immunoglobulin A Vasculitis (IgAV), and Alport Syndrome (AS). The treatment being tested is a medication called Sparsentan, which is given as an oral suspension. The purpose of the study is to evaluate the safety and effectiveness of Sparsentan in children with these kidney diseases.

Participants in the study will receive Sparsentan once daily for a period of 108 weeks. During this time, researchers will monitor the safety of the medication and observe any changes in the levels of protein in the urine, which is a key indicator of kidney health. The study aims to understand how well Sparsentan works in reducing protein levels in the urine and how the body processes the medication over time.

The study will also look at how many participants experience a complete or partial remission of their kidney disease symptoms, such as a significant reduction in protein levels in the urine. Additionally, researchers will track any side effects that occur during the study, including any that might lead to stopping the treatment. This information will help determine the overall safety and potential benefits of Sparsentan for treating these specific kidney diseases in children.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, the participant or their parent/legal guardian must provide signed informed consent. The participant must also provide assent before any procedures begin.

  2. Step 2

    Initial assessment

    An initial assessment is conducted to ensure eligibility. This includes checking that the participant has an estimated glomerular filtration rate (eGFR) of at least 30 mL/min/1.73 m² and a mean seated blood pressure within the normal range for their age and height.

  3. Step 3

    Medication administration

    The participant will receive a medication called sparsentan in the form of an oral suspension. This medication is taken once daily.

  4. Step 4

    Treatment duration

    The treatment with sparsentan will continue for a period of 108 weeks. During this time, the participant's response to the medication will be monitored.

  5. Step 5

    Monitoring and assessments

    Throughout the study, regular assessments will be conducted to monitor the participant's health and the effects of the medication. This includes measuring changes in protein levels in the urine and other relevant health indicators.

  6. Step 6

    Completion of the study

    At the end of the 108-week period, a final assessment will be conducted to evaluate the overall effects of the treatment.

Who can join the trial?

10 criteria

  • The person or their parent/legal guardian must be willing and able to sign a consent form, and the person must agree to participate before any tests are done.
  • The person must have an estimated glomerular filtration rate (**eGFR**) of at least 30 mL/min/1.73 m². **eGFR** is a test that measures how well the kidneys are working.
  • The person must have a blood pressure that is within the normal range for their age, sex, and height.
  • For Population 1: The person must be a boy or girl who is at least 1 year old but younger than 18 years old at the start of the study.
  • For Population 1: The person must have a urine protein/creatinine ratio (**UP/C**) of at least 1.5 g/g at screening. **UP/C** is a test that measures the amount of protein in the urine. They must also have one of the following:
    • A kidney biopsy showing specific patterns related to certain kidney diseases, and they must have protein in their urine despite treatment with certain medications.
    • Documentation of a genetic mutation in a specific kidney cell protein related to certain kidney diseases. If they have this mutation, a kidney biopsy is not needed.
    • A kidney biopsy showing a specific pattern with a medical history and symptoms that match a certain type of kidney damage.
    • For Population 2: The person must be a boy or girl who is at least 2 years old but younger than 18 years old at the start of the study.
    • For Population 2: The person must have a **UP/C** of 0.6 g/g or less at screening. They must also have one of the following:
      • A kidney biopsy confirming certain kidney diseases.
      • A diagnosis of a specific kidney disease through genetic testing, which involves certain mutations in specific genes.

Who cannot join the trial?

10 criteria

  • Patients with other serious health conditions that might interfere with the study.
  • Patients who are pregnant or breastfeeding.
  • Patients who have had a recent major surgery.
  • Patients who are currently participating in another clinical trial.
  • Patients with a history of drug or alcohol abuse.
  • Patients who have an allergy to the study medication.
  • Patients with uncontrolled high blood pressure.
  • Patients with severe liver or kidney disease.
  • Patients who are unable to follow the study procedures.
  • Patients who have a history of certain heart conditions.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Sparsentan is an investigational medication being studied for its potential to treat certain kidney diseases that cause high levels of protein in the urine, known as proteinuric glomerular diseases. In this clinical trial, sparsentan is given as an oral suspension, which means it is a liquid form that is taken by mouth. The main goals of the trial are to evaluate how safe and well-tolerated sparsentan is for children with these kidney conditions and to see how it affects the levels of protein in their urine over a period of 108 weeks.

What is already known about the treatment

Sparsentan – Sparsentan is administered as an oral suspension, taken once daily. It is currently being studied in clinical trials for its safety and effectiveness in treating proteinuric glomerular diseases, such as focal segmental glomerulosclerosis, minimal change disease, and others. The medication works by blocking specific receptors in the body, which helps reduce protein loss in urine. It is classified as an angiotensin receptor blocker and endothelin receptor antagonist.

Investigated diseases

  • Focal Segmental Glomerulosclerosis (FSGS)

    A kidney disorder characterized by scarring in the glomeruli, which are tiny structures within the kidneys that filter waste from the blood. This scarring leads to protein leaking into the urine, a condition known as proteinuria. Over time, FSGS can cause the kidneys to lose their ability to filter blood effectively.

  • Minimal Change Disease (MCD)

    A kidney disease that primarily affects children, causing nephrotic syndrome, which is characterized by high levels of protein in the urine, low levels of protein in the blood, and swelling. The disease is termed "minimal change" because the kidney tissue appears nearly normal under a regular microscope, but changes can be seen with an electron microscope.

  • Immunoglobulin A Nephropathy (IgAN)

    A kidney disease that occurs when IgA, a type of antibody, builds up in the kidneys, leading to inflammation that can affect the kidneys' ability to filter waste from the blood. This condition often progresses slowly over many years and can result in blood and protein in the urine.

  • Immunoglobulin A Vasculitis (IgAV)

    A disease that causes small blood vessels to become inflamed and can affect the skin, joints, intestines, and kidneys. It is often characterized by a purplish rash, joint pain, and abdominal pain, and can lead to kidney issues similar to those seen in IgA nephropathy.

  • Alport Syndrome (AS)

    A genetic condition characterized by kidney disease, hearing loss, and eye abnormalities. It affects the glomeruli in the kidneys, leading to progressive loss of kidney function and often results in blood and protein in the urine. The condition is caused by mutations in genes that affect the type IV collagen found in the kidneys, ears, and eyes.

Trial detailsLast updated 7 Oct 2026
Age0-17PhasePhase IITrial ID2023-505497-14-00Protocol codeRTRX-RE021-201Estimated enrolment67 patientsSponsorTravere Therapeutics Inc.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.